RRoche Read More RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline2026-02-17 Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a…
